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Patient outcomeBCL9/9L proteins enhance the transcriptional output of the β-catenin/TCF transcriptional complex and contribute
critically to upholding the high WNT signaling level required for stemness maintenance in the intestinal epitheli-
um. Here we show that a BCL9/9L-dependent gene signature derived from independent mouse colorectal cancer
(CRC) models unprecedentedly separates patient subgroups with regard to progression free and overall survival.
We found that this effect was by and large attributable to stemness related gene sets. Remarkably, this signature
proved associated with recently described poor prognosis CRC subtypes exhibiting high stemness and/or
epithelial-to-mesenchymal transition (EMT) traits. Consistent with the notion that highWNT signaling is required
for stemnessmaintenance, ablating Bcl9/9l-β-catenin inmurine oncogenic intestinal organoids provoked their dif-
ferentiation and completely abrogated their tumorigenicity, while not affecting their proliferation. Therapeutic
strategies aimed at targetingWNT responsesmay be limited by intestinal toxicity. Our ﬁndings suggest that atten-
uatingWNT signaling to an extent that affects stemnessmaintenance without disturbing intestinal renewal might
be well tolerated and prove sufﬁcient to reduce CRC recurrence and dramatically improve disease outcome.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Themajority of colorectal cancers (CRC) are caused by a common set of
genetic alterations, whereby mutational activation of the WNT pathway
represents a key oncogenic initiation event (Cancer Genome Atlas, 2012;
Fearon and Vogelstein, 1990) that remains critical for tumor maintenance
and progression (Dow et al., 2015). Molecular CRC subtypes based upon
gene expression patterns have recently been described that likely reﬂect
further genetic and functional heterogeneity and are associated with pa-
tient outcome (Budinska et al., 2013; Marisa et al., 2013; Sadanandam
et al., 2013). Across these data sets, subtypes enriched for mesenchymal
and/or stem-cell-like features were associated with poorest outcome
(Budinska et al., 2013; Guinney et al., 2015; Marisa et al., 2013;
Sadanandam et al., 2013).
In the intestinal epithelium a gradient of WNT-β-catenin signaling
along the crypt-villus axis regulates cellular hierarchy and continuous. This is an open access article underrenewal. HighWNT signaling is required for the establishment of intestinal
stem cells (ISC) at the crypt bottom, where neighboring Paneth cells
constitute the major source of WNT ligands (Clevers, 2013; Sato et al.,
2011b). Numerous observations indicate that analogously, WNT-β-catenin
signaling contributes to CRC progression through the maintenance of a
stem-cell-like state in a subset of cancer cells (Anastas and Moon, 2013;
Nguyen et al., 2012).
CanonicalWNT signaling output ismediated through a core complex
of β-catenin and TCF/LEF transcription factors, which in the intestine is
critical for the establishment and proliferation of the normal crypt epi-
thelium, as ablation of either TCF or β-catenin results in prompt crypt
loss (Fevr et al., 2007; Ireland et al., 2004; Korinek et al., 1998; van Es
et al., 2012). Whereas the C-terminal domain of β-catenin recruits pro-
teins involved in chromatin remodeling and transcriptional activation
that are not β-catenin speciﬁc (Mosimann et al., 2009; Valenta et al.,
2012), its N-terminal domain selectively binds Bcl9 or Bcl9l, two likely
redundant paralogs which serve as adaptors for additional partner pro-
teins and thereby contribute to further enhancingWNT-β-catenin tran-
scription (Valenta et al., 2012). Despite this apparent auxiliary role, Bcl9the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1933A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943proteins are essential for mouse development, as their ablation is lethal
at E10 (Cantù et al., 2014). Yet full blockade of WNT signaling through
ablatingWNTless (Wls) or Porcupine,which are critical for the secretion
of WNT ligands, results in a stronger phenotype with pre-gastrulation
lethality at E7 (Biechele et al., 2011; Fu et al., 2009). In mammalian
cells overexpression and RNAi gene knock-down experiments con-
ﬁrmed that Bcl9 proteins contribute to, but are not essential for WNT-
β-catenin transcription (Brack et al., 2009; Brembeck et al., 2004;
Hoffmans et al., 2005; Mani et al., 2009; Valenta et al., 2012).
Our previouswork revealed that ablation of Bcl9/9l in the adultmouse
is dispensable for normal homeostasis of the gastrointestinal epithelium.
Though there were no overt anomalies in intestinal homeostasis, mice
lacking Bcl9/9l proteins were deﬁcient in epithelial regeneration, as
shown in an ulcerative colitis model, pointing to a possible deﬁciency in
ISC expansion and/or maintenance (Deka et al., 2010). The role of Bcl9/
9l in the regulation of stemness properties became overtly apparent in a
mouse chemical carcinogenesis model of CRC, which combines exposure
to the mutagen azoxymethane (AOM) and the inﬂammatory agent dex-
tran sulphate sodium (DSS) and serves as a model for constitutively
WNT driven human CRC (Greten et al., 2004; Taketo and Edelmann,
2009). Ablation of Bcl9/9l proteins resulted in virtual loss of ISC markers,
concurrentlywithmarked down-regulation of genes related to EMT and a
group of selectedWNT targets (Deka et al., 2010). The control of ISC iden-
tity appears to depend upon WNT signaling strength (Schuijers et al.,
2015). Here we show that the apparently rather subtle tuning role of
Bcl9 proteins in WNT β-catenin signaling may by critical for upholding
stemness traits in CRC, contributing to the functional heterogeneity
among molecular subtypes and determining patient outcome.
2. Materials and Methods
2.1. APC/Kras-mutant Organoids
The culture of small intestinal crypts from Apc/Kras animals has been
previously described (Sato et al., 2011a; van Es and Clevers, 2015). Brieﬂy,
crypts were isolated and puriﬁed, embedded in 50 μl matrigel drops
(Corning, 356231) and overlaidwith 500 μl organoidmedium (Advanced
DMEM/F12 (Life Technologies, 11320-082), 2mMGlutaMAX (Life Tech-
nologies, 35050-061), 10 mM HEPES buffer (Sigma, 83264-100ML-F),
0.5 U/ml Penicillin/Streptomycin (Life Technologies, 15070-063), N2
(Life Technologies, 17502-048), B27 (Life Technologies, 12587-010).
Organoids were expanded in growth factor supplemented medium for
5 days: 50 ng/ml mEGF (Life Technologies, PMG8041), 100 ng/ml
mNoggin (Peprotech, 250–38), 500 ng/ml hRSPO1 (R&D, 4645-RS-
025) according to Fig. 4A. EGF and R-spondin were subsequently re-
moved to select for organoids that had lost the wild-type Apc copy.
The medium was changed every 2 days. Established mutant lines were
passaged every four days by mechanical disruption with a bent P1000
pipette tip. Allograft assays were performed by subcutaneously injecting
50′000 organoid cells mixed 1:1with 100 μl matrigel. Receiver NOD scid
gamma mice (Jackson laboratory, 005557) were bred by the Animal Fa-
cility of Epalinges, University of Lausanne, Switzerland. Allograft length
and width was determined by caliper measurement, volume was calcu-
lated by use of themodiﬁed ellipsoid formula: 1 / 2(Length ×Width^2).
In vitro recombination by R26-CreERT2was induced by applying 1 μM4-
hydroxytamoxifen (Sigma, H7904) to the culture medium.
2.2. Human CRC Datasets
Wemade use of the following CRC Gene Expression Omnibus (GEO)
databases: GSE12945, GSE14333, GSE17538, GSE33113, GSE37892,
GSE39582 and GSE41258, all generated using the Affymetrix HG U133
Plus 2.0 platform. Gene expression data from the PETACC-3 (Pan-
European Trials in Alimentary Tract Cancers) trial patients were gener-
ated as previously described (Popovici et al., 2012) using the ALMAC
Colorectal Cancer DSA platform (Craigavon, Northern Ireland), whichis a customized Affymetrix chip that includes 61′528 probe sets map-
ping to 15′920 unique Entrez Gene IDs. A set of 752 colorectal cancer pa-
tients of stage II (108/752) and stage III (644/752) was used here.
2.3. Signature Scores and Survival Analysis
Bcl9/9l-dependent genes with coinciding signiﬁcant differential ex-
pression (log2 fold change of N1 and an adjusted p value of b0.001) in
both the AOM/DSS and Apc/Kras model were used to identify human
homologs (NCBI) and constitute the BCL9/9L-KO signature. Optimal
microarray probe sets were selected according to Li et al. (2011). The
BCL9/9L-KO signature is composed of 300 down-regulated and 78 up-
regulated human genes. Of these, 215 (71%) down-regulated and 66
(84%) up-regulated genes were contained in the PETACC-3 dataset
(Table S1). The BCL9/9L-KO signature score was deﬁned by subtracting
the average of the 300 human homologs down-regulated upon ablation
of Bcl9/9l from the average of the 78 human homologs up-regulated
(or 215 down-regulated and 66 up-regulated genes in the PETACC-3
dataset, respectively). Effects of the BCL9/9L-KO signature on DFS and
OS were investigated using Kaplan–Meier estimates with patients cate-
gorized into two groups by median split and logrank tests for assessing
signiﬁcance. The Cox proportional hazardsmodelwas used to assess the
prognostic value of interquartile range (IQR)-standardized values in
each patient cohort separately. These survival analyses were performed
with the R package survival. Meta-analysis and forest plots were done
using theMeta package in R.
2.4. Association Between Known CRC Subtypes and BCL9/9L-KO Signature
The association between the BCL9/9L-KO signature score standard-
ized by IQR division and subtypes from three studies (Guinney et al.,
2015; Marisa et al., 2013; Sadanandam et al., 2013) was determined
by performing a non-parametric Wilcoxon test to evaluate whether
the median of BCL9/9L-KO signature score for each subtype was differ-
ent from the median of all patients (2.455313).
3. Results
3.1. RNA Sequencing Reveals a Robust Bcl9/9l-dependent Gene Expression
Signature Across Independent Mouse CRC Models
We previously made use of a chemically induced mouse CRCmodel,
which combines exposure to the mutagen azoxymethane (AOM) and
the inﬂammatory agent DSS and serves as a model for constitutively
WNT driven human CRC (Greten et al., 2004; Taketo and Edelmann,
2009), to investigate the genome-wide impact of Bcl9/9l ablation on
gene expression. Among the striking changes, down-regulation of se-
lectedWNT targets, ISC markers and EMT-related genes was particular-
ly noticeable (Deka et al., 2010). AOM/DSS tumors are typically initiated
by β-catenin stabilizing mutations (Greten et al., 2004). We therefore
sought to validate our observations in an independent mouse CRC
model driven by loss of Apc and oncogenic Kras, which are common
oncogenic events in human CRC (Janssen et al., 2006). Apc1638N and
villin-driven KrasG12V alleles (hereafter Apc/Kras) were crossed into a
homozygous Bcl/9lloxP/loxP background (Deka et al., 2010). Bcl9/9l dele-
tion in the intestinal epithelium was driven by villin-Cre; mice lacking
the villin-Cre transgene served as controls (Fig. 1A).
To compare Bcl9/9l-dependent phenotypes between the two tumor
modelswe ﬁrst assessed expression of the genes thatweremost strong-
ly down-regulated in AOM/DSS tumors lacking Bcl9/9l (hereafterWNT/
stemness/EMT reference genes) (Deka et al., 2010) (Fig. S1A). Similar to
AOM/DSS tumors, ablation of Bcl9/9l in Apc/Kras colon tumors also re-
sulted in down-regulation of WNT/stemness/EMT reference genes
(Fig. S1B). Like AOM/DSS tumors, Apc/Kras colon tumors also expressed
vimentin within tumor cells, albeit to a somewhat lesser extent, and
typically the basement membrane underlying vimentin expressing
1934 A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943tumor cells appeared to be discontinuous. In both tumor models dele-
tion of Bcl9/9l resulted in complete abrogation of vimentin expression
and restored basementmembrane integrity (Fig. S1C, D). TheseﬁndingsFig. 1. Amurine CRC derived BCL9/9L-KO signature is associatedwith vastly improved survival
igenesis protocol as described (see Materials and Methods and ref. Neufert et al. (2007)). Indep
ducing WNT-activated CRC (Janssen et al., 2006). (B) RNAseq: Correlation of log2 fold chang
determined and tested for the hypothesis r= 0. (C) Venn diagram (approximated proportions)
right: respective up-regulated genes. Humanhomologs of commonmouse geneswere selected a
et al., 2011), resulting in 300 down-regulated (negatively weighted) and 78 up-regulated (posi
nature”, is shown in Table S1 andwas used for probing humanCRC patient databases. (D) Kaplan
microarray databases (Affymetrix HG U133 Plus 2.0; GSE17538). DFS and OS of patients with h
tients according to amedian split. (E)Meta-analysis of all CRC patientmicroarray databases. The
forest plots of HRs for one inter-quartile unit of the signature score.clearly suggested that ablation ofBcl9/9l inApc/Kras tumors by and large
phenocopies gene expression changes observed in the AOM/DSSmodel.
It is noteworthy that mice bearing Bcl9/9l-KO Apc/Kras tumors survivedin human CRC. (A) Bcl9/9l-KO and control littermates were subjected to a chemical tumor-
endently, Apc/Kras alleles were crossed into Bcl9/9l-KO and wild-type background for in-
es between wild-type and Bcl9/9l-KO AOM/DSS and Apc/Kras tumors. Pearson's r were
. Left: genes down-regulated in Bcl9/9l-KO samples of both Apc/Kras and AOM/DSS tumors;
ccording to NCBI and corresponding optimalmicroarray probe sets chosen as described (Li
tively weighted) human probe sets. This gene list, hereafter referred to as “BCL9/9L-KO sig-
–Meier estimates for DFS andOS of CRC patients from one of the largest public humanCRC
igher (black) or lower (red) expression of the BCL9/9L-KO signature after subdividing pa-
relative strength of association of the BCL9/9L-KO signaturewithDFS andOS is presented as
1935A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943signiﬁcantly longer than controls, presumably due to a delay in tumor
growth (Fig. S1E, F).
To extend the gene expression analysis beyondWNT/stemness/EMT
reference genes and establish a robust signature of overlapping changes
across these CRC models, we subjected wild-type and Bcl9/9l-ablated
tumor samples fromAOM/DSS and Apc/Kras tumors to RNA sequencing.
Bcl9/9l-dependent gene expression changes correlated positively and
highly signiﬁcantly across the two tumor models (Fig. 1B).
3.2. A BCL9/9L-knockout Signature is Associated With Improved
Progression-free and Overall CRC Patient Survival
The list of genes that were differentially expressed upon ablation of
Bcl9/9l and common to both the RNA sequencing data sets of AOM/DSSFig. 2. Loss of Bcl9/9l is correlatedwith loss ofWNT, EMT and stemness signatures, and increase
versuswild-type tumors from three differentmodels. Gene signatures relating to intestinal stem
gene setwhose composition and origin are listed in Table S3. Eachﬁeld depicts a single GSEA of
a negatively and positively enriched signature, respectively. The color code represents normaliand Apc/Kras tumors comprised 359 down- and 107 up-regulated genes
(Fig. 1C), for which 300 and 78 human homologs, respectively were
identiﬁed (hereafter BCL9/9L-KO signature) (Table S1). This BCL9/9L-
KO signature was used to probe the largest public human CRC microar-
ray database (AffymetrixHGU133Plus 2.0) containing both disease free
(DFS) and overall survival (OS) information (Fig. 1D). Kaplan–Meier
analysis of patient samples subdivided into two groups by median
split revealed a striking positive association of the BCL9/9L-KO signature
with a more favorable outcome (Fig. 1D). Additional human CRC data-
bases were probed analogously, including a set of 752 stage II and III
samples from the PETACC-3 clinical trial (Van Cutsem et al., 2009),
which was generated using a different platform (see Experimental Pro-
cedures) and contained high quality clinical follow-up data (Popovici
et al., 2012). Consistently, and across different platforms, these analysesddifferentiation traits. Heatmap of normalizedGSEA scores in transcriptomes of Bcl9/9l-KO
ness,WNT, EMT or differentiationwere selected from the literature. Each row represents a
the respective gene signature in the corresponding tumor dataset; insets show examples of
zed enrichment scores.
Fig. 3. Association between the BCL9/9L-KO signature and stemness subtypes in independent CRC classiﬁcations. (A) Association of the BCL9/9L-KO signature with ﬁve CRC subtypes
deﬁned by Sadanandam et al. (2013) in 752 patients from the PETACC-3 clinical trial (Popovici et al., 2012; Van Cutsem et al., 2009). Patients with BCL9/9L-KO signature scores below
the median are shown in red (BCL9/9L-WT-like), those with scores above the median are shown in black (BCL9/9L-KO-like). The insets display the results of a Wilcoxon test evaluating
the difference between the median of the BCL9/9L-KO signature score for each subtype and the median of all patients (2.455313). (B) Analogous analysis to (a) with the CRC subtypes
described by Marisa et al. (2013). (C) Analogous analysis to (a) with the consensus molecular subtypes (CMS) described by the Colorectal Cancer Subtyping Consortium (Guinney
et al., 2015).
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1937A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943corroborated that hazard of relapse or death was highly signiﬁcantly re-
duced in patients with tumor proﬁles associated with the BCL9/9L-KO
signature (Fig. 1E). Remarkably, the prognostic capacity of the BCL9/
9L-KO signature was observed irrespective of tumor stage and indepen-
dent of molecular parameters as revealed by multivariable analysis
(Table S2). Speciﬁcally, there was no important effect modulation by
other variables such as BRAF, KRAS or P53 mutations, or the microsatel-
lite instability status.
3.3. Loss of BCL9/9L Results in Shifting the Stemness to Differentiation Gene
Expression Balance Towards Differentiation
To assess to what extent the prognostic value of the BCL9/9L-KO sig-
nature could be attributed to biologic functions, a wide array of pub-
lished gene sets relating to intestinal WNT targets, stemness, EMT, and
differentiation (Fig. 2, Table S3) was assessed by gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) for enrichment in the
transcriptomes of BCL9/9L-KO tumors. Each gene set was assessed indi-
vidually as exempliﬁed in the two insets, given a score after normaliza-
tion for the size of the relevant set, and the scores represented as a
heatmap (Fig. 2). Unambiguously, all examined WNT- stemness-, and
EMT-related gene sets were negatively enriched, while differentiation-
related sets were positively enriched within the transcriptomes of
knockout tumors. Remarkably, consistent enrichment scores were ob-
served across the threemouseCRCdatasets, i.e. thenewRNA sequencing
sets from AOM/DSS and Apc/Kras tumors, and our previously reported
Affymetrix microarray data set from DMH/DSS tumors (GSE21576)
(Deka et al., 2010). See Fig. 1.
Importantly, a list comprising all genes common to the individual
functional gene sets and the BCL9/9L-KO signature (highlighted in
Table S1) proved correlated with patient outcome similar to the entire
BCL9/9L-KO signature (Fig. S2), corroborating that genes comprised in
these WNT-, stemness-, EMT-, and differentiation-related gene sets by
and large determined its prognostic value.
3.4. The BCL9/9L-KO Signature is Negatively AssociatedWithHigh Stemness
CRC Subtypes
Recently, gene expression subtypes of CRC have been reported,
which are associated with patient outcome (Budinska et al., 2013;
Guinney et al., 2015; Marisa et al., 2013; Sadanandam et al., 2013). We
classiﬁed patient samples of the PETACC dataset according to themolec-
ular subtypes deﬁned by Sadanandam et al. (2013) (Fig. 3A) andMarisa
et al. (2013)) (Fig. 3B) and consensusmolecular subtypes (CMS) recent-
ly reported by the Colorectal Cancer Subtyping Consortium (CRCSC)
(Guinney et al., 2015) (Fig. 3C) and asked to what extent the BCL9/9L-
KO signature was enriched in any of these subtypes. Remarkably,
there was a highly signiﬁcant negative association of the BCL9/9L-KO
signature with the “Stem-like” (Sadanandam et al., 2013), “C4/CSC”
(Marisa et al., 2013) and “CMS4/mesenchymal” (Guinney et al.,
2015)subtypes that were all characterized by high stemness and/or
EMT traits and associated with poor prognosis. BCL9/9Lwere expressed
above background across all patient samples, and to our knowledge
there are no reports on inactivating BCL9/9L mutations in human tu-
mors. The BCL9/9L-KO signature was therefore not expected to show
strong positive enrichment in any of the other subtypes. It is noteworthyFig. 4. Loss of Bcl9/9l accelerates differentiation of intestinal organoids and abrogates their tumo
tantmicewere cultivated for 5 days as described (seeMaterials andMethods and ref. Sato et al. (
Apc loss-of-heterozygosity that grew independently of those growth factors. (B) Morphology o
large proportion of spheroids, Bcl9/9l-KO cultures were virtually devoid of spheroids and conta
spheroids. (D) Organoid-derived allografts of 50,000 cells injected subcutaneously in NOD scid
mitted tumor size. (F) Resected allografts. Scale bar: 500 μm. (G) Representative picture of a NOD
allograft (left ﬂank), consisting mostly of scar tissue. (H) Left panel: Representative images of
large, moderately differentiated adenocarcinoma of intestinal origin. Broad spectrum cytoker
panel: Representative images of consecutive sections of a Bcl9/9l-KO allograft. Histopathological
origin (bottom left). Large parts of the allograft consist of ﬁbroblastic, presumably scar tissue (that there was a signiﬁcant correlation between expression of stemness
traits and BCL9L and to a lesser extent BCL9 gene expression levels
(Fig. S3A). Accordingly, BCL9L, but not BCL9 expressionwas signiﬁcantly
correlated to poor outcome in most databases (Fig. S3B).
3.5. BCL9/9L-ablation in Intestinal Organoids Results in Increased
Differentiation and Loss of Tumorigenicity
Recently, conditions have been established allowing to culture and
passage intestinal crypt-derived epithelial organoids, which recapitu-
late the differentiation hierarchy of the small intestinal epithelium
(Sato et al., 2011a; van Es and Clevers, 2015). We isolated and cultured
Bcl9/9l-wild-type or Bcl9/9l-KO small intestinal crypts from Apc/Kras
mice (Janssen et al., 2006), initially in the presence of R-spondin and
EGF to stimulate the WNT pathway and expand the cultures as de-
scribed (Sato et al., 2011a). After ﬁve days these growth factors were
withdrawn to select for organoids that had lost the remaining wild-
type Apc allele and had therefore become independent of external
WNT stimulation (Sato et al., 2011a) (Fig. 4A). Apc/Kras-driven crypt
cultures grewmostly as undifferentiated spheres (Fig. 4B), as described
for mutant adenoma-derived organoids (Sato et al., 2011a). In the
absence of Bcl9/9l, however, budding structures resembling normal in-
testinal organoids (Sato et al., 2011b) were vastly predominant over
spherical organoids (Fig. 4B, C), indicative of a more differentiated
state. The Bcl9/9l status was veriﬁed by qRT-PCR and conﬁrmed that
there was no selection of escaping Bcl9/9l-wild-type organoids within
Bcl9/9l-KO cultures (Fig. S4A). Expression of the Bcl9/9l-dependent
WNT/stemness/EMT reference genes identiﬁed in AOM/DSS colon tu-
mors proved at least in part down-regulated in Bcl9/9-KO organoids
(Fig. S4B–D), despite their small intestinal origin, and conversely, intes-
tinal differentiation markers including villin and keratin 20(Dow et al.,
2015) were up-regulated (Fig. S4E). Both wild-type and Bcl9/9l-KO
organoid cultures grew at similar proliferation rates (Fig. S4F), while
maintaining their distinct morphology over serial passaging.
Next, we assessed the tumorigenicity of Bcl9/9l-wild-type or Bcl9/9l-
KO Apc/Kras organoids in NOD scid gammamice.Whereas Bcl9/9l-wild-
type subcutaneous allografts grew exponentially, Bcl9/9l-KO grew only
for up to one week before tumors started regressing and became virtu-
ally impalpable (Fig. 4D). Allografts were collected at day 26 after injec-
tion when tumors had reached legally admitted size limits. As expected
from tumor palpation, wild-type grafts weighed substantially more
than Bcl9/9l-KO counterparts (Fig. 4E). Macroscopically, some wild-
type tumors showed signs of rapid growthwith central necrosis, where-
as Bcl9/9l-KO grafts appeared as scar tissue (Fig. 4F, G). Histologically,
wild-type grafts appeared as low-grade adenocarcinomas of intestinal
origin, with high resemblance to human CRC, whereas Bcl9/9l-KO grafts
contained only small islets of highly differentiated epithelial structures
reminiscent of normal intestinal epithelium, which were surrounded
by ﬁbroblastic and inﬂammatory tissue, compatible with ongoing
tumor resorption and concomitant scarring (Fig. 4H).
3.6. Induced Bcl9/9l Ablation in Wild-type Intestinal Organoids and
Pre-established Tumors Phenocopies Constitutive Bcl9/9l Inactivation
The strong association of Bcl9/9l-dependent phenotypes with CRC
patient outcome prompted us to address to what extent ablatingrigenicity. (A) Small intestinal crypts derived from Bcl9/9l-wild-type or -KO Apc/Krasmu-
2011a)). Subsequent removal of EGF and R-spondin resulted in selection of organoidswith
f organoids one week after growth factor removal. Bcl9/9l-wild-type cultures contained a
ined mostly budding organoids. Scale bars: 100 μm. (C) Quantiﬁcation of undifferentiated
gammamice. (E)Weight of allografts collected after 26 days upon reaching the legally ad-
scid gammamouse exhibiting a largewild-type allograft (rightﬂank) and a smallmutant
consecutive sections of a Bcl9/9l-wild-type allograft. Histopathological analysis revealed a
atin staining conﬁrms the large content of viable epithelial cells. Scale bars: 50 μm. Right
analysis revealed small residual andwell differentiated islets of epithelial cells of intestinal
bottom right) with residual inﬂammation. Scale bars: 50 μm.
1938 A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943Bcl9/9l in wild-type intestinal organoids or pre-established wild-type
tumors was able to recapitulate the observed gene expression changes
and thereby validate the BCL9/9L-β-catenin interaction as a potential
therapeutic target. 4-hydroxytamoxifen (4-OHT) exposure of intesti-
nal organoids derived from of Apc/Kras mice expressing R26-CreERT(Ventura et al., 2007) and carrying Bcl9/9lloxP/loxP alleles resulted in a
rapid shift in the ratio between sphere-like and budding organoids,
with progressive disappearance of spheroid structures over 48 h,
whereas the proportion of sphere-like organoids remained stable in
the untreated controls (Fig. 5A–C). This phenotype was not observed
1939A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943in 4-OHT treated wild-type spheroids (Fig. 5C) and correlated with
Bcl9/9l expression levels (Fig. S5A).
Analogously, induction of Bcl9/9l deletion in pre-established AOM/
DSS tumors (Fig. 5D) resulted, as early as two weeks after tamoxifen-mediated villin-CreERT activation, in phenotypic changes that by and
large recapitulated those observed in constitutively Bcl9/9l-ablated tu-
mors (Fig. 5E, F and Fig. S5B). One of the hallmarks of wild-type AOM/
DSS tumors is a widespread expression of vimentin within the tumor
1940 A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943epithelium paired with discontinuous basement membrane staining
(Fig. S1C, upper panel). Upon Bcl9/9l ablation vimentin expression
was completely abrogated and the underlying basement membrane
regained normal looking continuity (Deka et al., 2010) (Fig. S1C, lower
panel). These striking phenotypic changeswere recapitulated upon con-
ditional Bcl9/9l-ablation. Tumor areaswith residual vimentin expression
also showed residual Bcl9 protein, pointing to uneven tamoxifen perme-
ation into tumor tissue and indicating that these Bcl9/9l-dependent
phenotypic changes are cell autonomous (Fig. 5E). Despite residual
Bcl9/9l expression, 14 out of the 18 WNT/stemness/EMT reference
genes (Fig. S1A) were down-regulated signiﬁcantly and proportionally
to Bcl9/9l expression levels (Fig. 5F).
Taken together these ﬁndings demonstrated that Bcl9/9l-dependent
phenotypic changes are readily inducible inwild-type organoids as well
as pre-established AOM/DSS tumors.
3.7. Genetic Mimicry of a Putative BCL9/9L-β-catenin Inhibitor
To further validate the BCL9/9L-β-catenin interaction as a potential
therapeutic target and simulate its pharmacologic inhibition, we com-
bined Bcl9/9l knock-in alleles, in which only the β-catenin interaction
domains (HD2) were deleted (Cantù et al., 2014), with conditional
Bcl9/9l-null alleles (Deka et al., 2010) to generate villin-CreERT2-Bcl9/
9lloxP/ΔHD2mice (Fig. 6A). AOM/DSS tumors were generated prior to de-
leting the wild-type alleles as described in Fig. 5D. Similar to tumors
with induced Bcl9/9l ablation (Fig. 5E, F), tamoxifen administration
resulted in loss of vimentin expression in tumor areas that also showed
restored basement membrane integrity (Fig. 6B–D). Accordingly, ex-
pression of WNT/stemness/EMT reference genes was reduced propor-
tionally to Bcl9/9l expression (Fig. 6E).
Importantly, these experiments unequivocally established that
Bcl9/9l-KO phenotypes observed in CRC models were indeed mediated
by the Bcl9/9l-β-catenin complex and were not caused by β-catenin-
independent effects of Bcl9/9l as they have recently been reported to
occur during lens development (Cantù et al., 2014).
4. Discussion
It is accepted that the cellular hierarchy along the crypt villus axis
in the intestinal epithelium is maintained through aWNT signaling gra-
dient (Clevers, 2013; Sato et al., 2011b), yet themechanisms underlying
the translation of signaling strength into cell type speciﬁcation remain
largely unexplored. Clearly, the identity of ISCs depends critically
upon high WNT signaling. A transcriptional response to high WNT li-
gand concentrations, as they occur in the ISC niche where Paneth cells
act as a ligand source, has recently been described to trigger an
autoactivation loop of the transcription factor Ascl2, which together
with the β-catenin/TCF core complex activates genes that are essential
to establishing a stem cell state (Schuijers et al., 2015). We previously
showed that the BCl9/9L-β-catenin arm of WNT signaling contributes
to maintaining this stem cell state (Deka et al., 2010).
Here we extended these studies and corroborated our observations
in an independent mouse CRC model driven by oncogenic Kras and
loss of Apc, providing a basis for establishing an unbiased, robust signa-
ture of Bcl9/9l-dependent genes (Fig. 1A–C).The resulting BCL9/9L-KO
signature of human homologs proved of remarkable prognostic valueFig. 5. Induced loss of Bcl9/9l recapitulates constitutive phenotypes in vitro and in vivo. (A) Org
transgene as described in Fig. 4A. Bcl9/9l ablationwas induced through addition of 4-OHT to the
the 4-OHT treatment. Scale bar: 100 μM. (C) Quantiﬁcation of spheroids in 4-OHT-treated R26
controls. (D) Inducible ablation of Bcl9/9l proteins was investigated in vivo in AOM/DSS tum
DSS administration through the drinking water. Gene deletion was induced when mice
(E) Tamoxifen induced villin-CreERT2-mediated recombination resulted after 14 days inpatchy
revealed a remarkable overlap between absence of Bcl9 and vimentin staining and basementme
presence of epithelial vimentin. (F) Induction of villin-CreERT2 resulted in approx. 2-fold decrea
reﬂecting approx. 50% chimerismbetweenwild-type and Bcl9/9l-null tumor tissue. 14 out of 18
tumor samples, to an extent that was proportional to the decrease of BCL9/9L transcripts.when used to probe databases of human CRC transcriptomes, clearly
revealing that patients with tumor proﬁles resembling the KO signature
had a markedly better prognosis (Fig. 1D, E). GSEA revealed that pub-
lished gene sets relating to WNT signaling, intestinal stemness, and
mesenchymal (EMT) traits were consistently negatively enriched with-
in the individual transcriptomes of Bcl9/9l-KO mouse tumors, whereas
gene sets relating to differentiation were positively enriched (Fig. 2).
Importantly, the subset of genes common to both, these public gene
sets and the unbiased BCL9/9L-KO signature proved of virtually identical
prognostic value as the entire KO signature (Fig. S2). Altogether these
ﬁndings clearly suggest that the prognostic value of the BCL9/9L-KO
signature is by and large due to the attenuation of stemness andmesen-
chymal, and a concomitant gain in differentiation traits, as a conse-
quence of diminished WNT signaling. Remarkably, the BCL9/9L-KO
signature consistently correlated negatively with subtypes character-
ized by high stemness traits and poorest outcome (Fig. 3).
To assess the functional impact of modulating BCL9/9L expression in
an in vitro cell based-modelwe turned to a panel of humanCRC cell lines
that we had characterized previously (Christensen et al., 2012). While
expression of stemness traits in these cell lines correlated signiﬁcantly
with the recently described poor prognosis features (Budinska et al.,
2013; Guinney et al., 2015; Marisa et al., 2013; Sadanandam et al.,
2013), we did not notice any signiﬁcant correlation with BCL9/9L
expression. Also, xenografts of both stemness-high cell lines such as
SW480, or more differentiated lines such as HT29 resulted in high-
grade tumors with little resemblance to human CRC (data not shown),
which typically are of much lower grade. We therefore focused our
efforts on a recently described oncogenic intestinal organoidmodel har-
boringApc and Kras doublemutations (van Es and Clevers, 2015), which
upon allografting produced low grade tumors strongly resembling
human CRC (Fig. 4H) and in which we introduced conditional Bcl9/9l
knockout alleles. Apc/Kras-driven Bcl9/9l-null intestinal organoids
were unable to maintain a sphere-like phenotype and readily evolved
towards more differentiated budding structures, thereby completely
losing their tumorigenicity in allograft assays (Fig. 4), in accordance
with the notion that Bcl9/9l in the CRC models is critical for upholding
stemness traits.
Collectively, the highly signiﬁcant impact of Bcl9/9l-ablation on ex-
pression of stemness traits in mouse CRC models paired with the rela-
tively mild phenotype in the unchallenged normal epithelium renders
the BCL9/9L-β-catenin interface an attractive potential therapeutic tar-
get to target cancer stem cells (CSC) in human CRC. It should be empha-
sized that BCL9/9L were expressed across all patient samples (Fig. S2).
Pharmacologic inhibition of the BCL9/9L-β-catenin interaction might
therefore be of even greater beneﬁt than suggested by the correlation
of the BCL9/9L-KO signature with more favorable outcome (Fig. 1D, E).
To further validate the BCL9/9L-β-catenin complex as a potential
target we ﬁrst demonstrated using loxP-ﬂanked alleles and tamoxifen
inducible CreERT2 that Bcl9/9l-KO phenotypes could be rapidly induced
in intestinal organoids and also in pre-established AOM/DSS tumors
(Fig. 5). Our studies consistentlymade use of compound loss-of function
mutants, preventing addressing to what extent Bcl9 and Bcl9l paralogs,
which share the same highly conserved homology domains(Brembeck
et al., 2006), are functionally redundant. Inmost CRCdatabases stemness
traits correlatedwith BCL9L, but not BCL9 expression, pointing to poten-
tially different roles (Fig. S3B). It is of note, however, that knock-in miceanoid cultures were established from Apc/Kras Bcl9/9lloxP/loxP mice carrying a R26-CreERT2
culturemedium for 5 days. (B) Representative phase-contrast images 7 days after starting
-CreERT Apc/Kras Bcl9/9lloxP/loxP cultures as compared to untreated or R26-CreERT-negative
ors. The mice were injected intraperitoneally with AOM and subjected to three cycles of
showed symptoms of intestinal bleeding, typically 15 weeks after tumor induction.
Bcl9/9l deletion, possibly due to uneven tamoxifenpermeation. Consecutive tissue sections
mbrane integrity; inversely, areas of residual Bcl9 expression (asterisk) correlatedwith the
se of Bcl9/9l transcripts in bulk tumormRNA twoweeks after the ﬁrst tamoxifen injection,
WNT/stemness/EMT reference genes (Fig. S1A)were signiﬁcantly down-regulated in these
Fig. 6.Deletion of theBcl9/9l-β-catenin interaction domain recapitulates the loss of Bcl9/9l phenotype. (A)A knock-inmouse strainwithHD2deletions of both Bcl9/9l proteins,whichwere
shown to selectively lack the ability to interact with β-catenin (Cantù et al., 2014), was intercrossed with villin-CreERT2-Bcl9/9lloxP/loxPmice (Deka et al., 2010), generating mice heterozy-
gous for both ΔHD2 and Bcl9/9lloxP/loxP alleles. AOM/DSS tumorswere generated as described in Fig. 5D. Upon tamoxifen administration these tumors became chimeric for tumor tissue, in
which either only Bcl9/9l-ΔHD2was expressed, or Bcl9/9l-ΔHD2was co-expressed with undeleted Bcl9/9lloxP/loxP alleles. (B–D) Deletion of the wild-type Bcl9/9l alleles resulted in virtual
abrogation of vimentin (green) in tumor epithelium that became surrounded with a contiguous basementmembrane (laminin, red), as observed upon constitutive or induced ablation of
Bcl9/9l alleles (Fig. S1 and Fig. 5). Antibodies recognizing wild-type, but notΔHD2 Bcl9 proteins were unavailable. Still, tumor sampleswith different proportions of wild-type and Bcl9/9l-
deleted tissue suggested a correlation between Bcl9/9l expression and vimentin protein and transcript levels (C, D). The same tumor samples were used for immunohistochemistry (IHC)
and for determining Bcl9/9l transcript levels (n= 1;mean and SE values relate to technical replicates). Scale bar: 50 μm. (E) Twoweeks after the ﬁrst tamoxifen injection deletion of wild-
type Bcl9/9l in presence of Bcl9/9l-ΔHD2 resulted in signiﬁcant down-regulation of 14out of 18WNT/stemness/EMT reference genes thatwasproportional to the residual level ofwild-type
Bcl9/9l, thereby phenocopying the induced loss of Bcl9/9l (Fig. 5F).
1941A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943
1942 A.E. Moor et al. / EBioMedicine 2 (2015) 1932–1943in which the β-catenin binding sites of both Bcl9 and Bcl9l were se-
lectively deleted, phenocopied the loss of the entire proteins, demon-
strating unmistakably that the observed loss-of-Bcl9/9l phenotypes
were mediated by β-catenin. This was important as recently β-catenin-
independent functions of Bcl9/9l have been discovered (Cantù et al.,
2014) (Fig. 6). Furthermore, these experiments mimicked the action
of a potential inhibitor of the BCL9/9L-β-catenin interaction, which in
principle appears to be drugable by small molecules (de la Roche et al.,
2012; Hoggard et al., 2015; Sampietro et al., 2006) or peptides (Takada
et al., 2012).
The mechanisms underlying the transcriptional co-activation func-
tion of Bcl9/9 l, which appears to be critical for sustaining stemness-
related target genes (Fig. 2, Table S3), but not WNT targets involved in
cell proliferation (Fevr et al., 2007; Ireland et al., 2004; Korinek et al.,
1998; van Es et al., 2012), remain to be explored. Bcl9/9l proteins have
been described to function as adapters that recruit partner proteins
such as Pygopus (Pygo), which eventually may bridge to and modulate
the general transcriptional activation complex at the C-terminus of
β-catenin (Kramps et al., 2002; Mosimann et al., 2009; Valenta et al.,
2012). It remains unclear whether Bcl9/9l exerts its stemness mainte-
nance effects through selective transcriptional modulation of WNT tar-
get gene subsets, or through non-selectively enhancingWNT-β-catenin
transcriptional output, resulting in threshold-dependent triggering
of amplifying loops as described for Ascl2 (Schuijers et al., 2015).
Pharmacologic inhibition of the interaction of β-catenin with CBP, a
component of the general transcriptional activation complex recruited
to the C-terminus of β-catenin, has been reported to affect the balance
between undifferentiated and differentiated cell states in various tumor
models (Ring et al., 2014), supporting the possibility that general
tempering of WNT signaling output might be sufﬁcient for lessening
stemness maintenance.
Establishment and maintenance of stemness in the ISC niche re-
quires high WNT signaling. Mutational activation of WNT signaling in
CRC results in transcriptional output possibly exceedingWNT responses
observed in normal tissues (Rosin-Arbesfeld et al., 2003). Our ﬁndings
are compatible with the notion of a direct relation between WNT sig-
naling strength and stemness maintenance. They show that pruning
WNT-mediated stemness maintenance as observed upon inactivation
of Bcl9/9l affects the regenerative potential in both the normal intestinal
epithelium as well in CRC. Whereas the former is tolerated, reducing
the regenerative potential of tumors might prove sufﬁcient to signiﬁ-
cantly impact relapse, in accordance with the CSC model (Zeuner et al.,
2014). Combining such a stemness tuning strategy with an established
CRC treatment protocol therefore represents a promising therapeutic
strategy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.10.030.
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